Insight Molecular Diagnostics enters specimen collection pact with Quest for GraftAssureCore test

Insight Molecular Diagnostics Inc.

Agreement with Quest Diagnostics dated Feb 20, 2026 for specimen collection services related to GraftAssureCore dd-cfDNA test.
Quest will provide services for the PCR-based blood test measuring donor-derived cell free DNA.
Parties also agree to negotiate additional rights to GraftAssure technology for a specified period.
Specific fees and financial terms not disclosed in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).

Action: entry
Agreement: supply
Counterparty: Quest Diagnostics Incorporated
Effective: 2026-02-20

Exact text from the filing

On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-008169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.